Twist Bioscience stock advances MRD research with faster panels

Twist Bioscience launched its MRD Express product on October 29, giving cancer researchers access to custom molecular residual disease panels with turnaround times starting within one day. The details were published by National Law Review in a release carried from Business Wire.

Faster panels for cancer research

MRD testing looks for small amounts of tumor-derived material that remain after treatment. Twist said its new panels combine the higher sensitivity of tumor-informed testing with production speeds associated with tumor-naive workflows.

The panels can include up to 10,000 probes and support oncology research, biomarker discovery and assay development. Twist also highlighted bioinformatics design support, ecommerce ordering and touchless application programming interface ordering.

Chief Executive Emily Leproust said the offering is designed to remove the tradeoff between sensitivity and speed through improvements to manufacturing and automation within the company's existing high-throughput environment. The release also said the platform is intended to support higher volumes as MRD providers expand.

Results are the next catalyst

Twist is scheduled to report fiscal fourth-quarter and full-year results before the market opens on Thursday, November 12, 2026, followed by an 8:00 a.m. Eastern Time conference call. The report will give investors the next opportunity to assess demand, operating leverage and progress toward management's adjusted EBITDA breakeven objective.

Twist Bioscience stock traded at 136.90 euros on Lang & Schwarz at 13:04 CET on Saturday, October 31.

Real-time quote of Twist Bioscience stock provides the latest available market view.

Broader risk appetite remains relevant for biotechnology and growth shares; investors can follow the S&P 500 market theme for the wider US equity backdrop.

More news and analyses on Twist Bioscience stock